SYNTERA BIORISK
SpeciesPoultry & birdsReleaseFrance · 2026-09-07
  1. Global Overview
  2. Europe
  3. France
  4. Highly pathogenic avian influenza
Country–disease dossierFrance · Highly pathogenic avian influenza
View economic evidence Run scenarioCompare interventionsInspect BCR assumptions Vaccine & intervention marketTrade analysis
France cross-disease portfolio FRANCE DISEASE PROFILE · LINKED WORKSPACE

Highly pathogenic avian influenza

Official evidence, 18-region exposure and transparent national planning economics.

Profile readyEvidence + editable CBA
African swine feverofficially freeHighly pathogenic avian influenzacurrent outbreak low national risk levelBluetongueenzootic active btv3Bovine tuberculosisofficially free with residual outbreaksFoot-and-mouth diseaseofficially freePeste des petits ruminantsofficially freeNewcastle diseaseno current event in registered sourceClassical swine feverofficially freeSheep pox and goat poxofficially freeLumpy skin diseaseno active outbreak vaccination controls continueBovine viral diarrhoeaendemic control programmeJohne's diseaseendemic control framework current prevalence unavailableEpizootic haemorrhagic diseaseno current season outbreak after recent epidemic
Official disease status · 2026-09-02

Highly pathogenic avian influenza

One HPAI outbreak has been detected in the season beginning August 2026; the national risk level remains negligible since 3 June 2026.

Selected geography
France
Susceptible livestock
240.77m
Evidence nature
Observed / official
Exposure layer

France · susceptible livestock

IGN COG 2026
Exposure is livestock inventory—not inferred prevalence. Regional selection updates supported evidence; the CBA remains explicitly national because regional cost evidence is unavailable.
Validated exposure

France

Gallus poultry240.77m

Agreste SAA 2025 provisional observations; source grain retained.

Official signal at selected grain
  • current-season outbreaks1 outbreaks
  • 2025-2026 commercial outbreaks125 outbreaks
  • 2025-2026 non-commercial/captive outbreaks31 outbreaks
Observed economics · national/source scope
Observed direct loss · national
N/A
Published programme cost · source scope
approximately EUR100m second duck-vaccination campaign
Monetised trade effect
N/A

No compatible current France-specific direct-loss estimate is registered; no value is inferred.

Relevant wildlife & interface

Wildlife evidence

No compatible current national wildlife-population layer is registered.

Population denominators remain unavailable unless explicitly registered; qualitative host evidence is not converted into a count.
ILLUSTRATIVE

Illustrative scenario—country-specific intervention evidence unavailable.

The planning parameters are retained, but the BCR is not estimated in this public profile.

Open Impact CalculatorWhy these assumptions?
Control choices

Default option scenarios

  1. 01Mandatory duck vaccinationPlanning option retained for explicit activation in Scenario Lab
  2. 02Wild-bird and farm surveillancePlanning option retained for explicit activation in Scenario Lab
  3. 03Protection and surveillance zonesPlanning option retained for explicit activation in Scenario Lab
Trade & movement

Documented consequence

Infected premises are depopulated; protection and surveillance zones restrict poultry movements and some hunting activity.

The registered official source documents controls but not a compatible France-wide monetised consequence.
Evidence register

5 sources used in this view

Release principle: every France disease has a complete decision workspace. Missing observed economics stay visible as N/A; modelled planning values are separately labelled, editable and never presented as evidence.
Sustainability & One HealthCountry-specific GHG, AMU/AMR and biodiversity results remain withheld until compatible evidence is registered; none is inferred from the disease profile.
Request complete Decision Brief